ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

04 May 2023 09:00:01 By Nasdaq GlobeNewswire

Adagene Announces Updates to its Board of Directors

28 Apr 2023 07:00:11 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

18 Apr 2023 09:17:47 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

28 Mar 2023 16:30:06 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

14 Mar 2023 18:00:00 By Nasdaq GlobeNewswire

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

05 Mar 2023 19:39:30 By Nasdaq GlobeNewswire

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

05 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

16 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

21 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

10 Nov 2022 09:04:56 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

11 Oct 2022 16:03:00 By Nasdaq GlobeNewswire

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

10 Sep 2022 04:13:54 By Nasdaq GlobeNewswire

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

30 Aug 2022 17:25:00 By Nasdaq GlobeNewswire

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

29 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

26 May 2022 17:00:00 By Nasdaq GlobeNewswire

Adagene to Participate in Investor Conferences in May and June

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

08 Apr 2022 13:09:40 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

31 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

16 Mar 2022 07:00:00 By Nasdaq GlobeNewswire